Evotec achieves further milestones in TargetAD col

Evotec achieves further milestones in TargetAD collaboration with Janssen


Evotec achieves further milestones in TargetAD collaboration with Janssen
Source Press Release
Company Evotec, Johnson & Johnson
Tags Central Nervous System, Milestone
Date January 15, 2015

Hamburg, Germany - 15 January 2015: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the achievement of several small, but very important milestones in its TargetAD collaboration with Janssen Pharmaceuticals, Inc. ("Janssen" for the identification and selection of novel targets from Evotec's TargetAD database and for the transition of targets into the drug discovery process. These milestones were reached in 2014 which will be recognised in the financial year 2014.

These selections were achieved under the agreement between Evotec and Janssen, facilitated by Johnson & Johnson Innovation LLC, signed in November 2013. Under the terms of the agreement, Janssen and Evotec continue to collaborate to develop new drugs for Alzheimer's disease.

Janssen has the option to internalize selected targets and therapeutic candidates and progress them into pre-clinical and clinical development. Janssen funds target drug discovery research via a combination of defined research payments and progress-related milestones.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "It was only in July 2014 that we announced the achievement of the first milestones in our TargetAD collaboration together with Janssen. The recent achievement of two further milestones further validates our approach and is a testament to a highly productive collaboration. I would like to congratulate the teams from both companies on the excellent progress and wish them continued success moving forward in their quest for innovative Alzheimer's disease therapies."



http://www.evaluategroup.com/Universal/View.a...pe%22%3a1}